Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
4(80%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
1
20%
Ph not_applicable
1
20%
Ph phase_2
2
40%
Ph phase_3
1
20%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Completed(1)

Detailed Status

Recruiting3
Completed1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
4
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (40.0%)
Phase 31 (20.0%)
Phase 41 (20.0%)
N/A1 (20.0%)

Trials by Status

completed120%
recruiting360%
active_not_recruiting120%

Recent Activity

4 active trials
Showing 5 of 5
recruitingphase_2

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

NCT07062055
recruitingphase_4

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

NCT06764095
active_not_recruitingphase_2

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

NCT00929214
completednot_applicable

A Study of Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer

NCT02898727
recruitingphase_3

A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol

NCT04773366

Clinical Trials (5)

Showing 5 of 5 trials
NCT07062055Phase 2

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

Recruiting
NCT06764095Phase 4

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Recruiting
NCT00929214Phase 2

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

Active Not Recruiting
NCT02898727Not Applicable

A Study of Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer

Completed
NCT04773366Phase 3

A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
5